Publications of the Division of Health Economics

Journals with external peer review


T. Ran, S. B. Eichmüller, P. Schmidt, M. Schlander:
Reply to: Comments on "Cost of decentralized CAR T cell production in an academic non-profit setting"
International Journal of Cancer. Available online August 15, 2020. DOI: 10.1002/ijc.33253. 

T. Ran, S. B. Eichmüller, P. Schmidt, M. Schlander:
Cost of decentralized CAR T cell production in an academic non-profit setting.
International Journal of Cancer. Available online June 14, 2020. DOI: 10.1002/ijc.33156. 

M. Schlander:
HTA agencies need evidence-informed deliberative processes. Comment on “Use of evicence-informed deliberative processes by health technology assessment agencies aroung the globe.
International Jounral of Health Policy Management. Available online February 19, 2020. DOI: 10.34172/ijhpm.2020.22.

J.M. Heard, C. Vrinten, M. Schlander, C.M. Bellettato, C. van Lingen, M. Scarpa; MetabERN collaboration group:
Availability, accessibility and delivery to patients of the 28 orphan medicines approved by the European Medicine Agency for hereditary metabolic diseases in the MetabERN network.
Orphanet Journal of Rare Diseases, (2020) Jan 6;15(1):3.  DOI: 10.1186/s13023-019-1280-5.



T. Ran, C.-Y. Cheng, B. Misselwitz, H. Brenner, J. Ubels, M. Schlander:
Cost–effectiveness of colorectal cancer screening strategies: A systematic review.
Clinical Gastroenterology and Hepatology, (2019) 17(10) 1969-1981.
DOI: 10.1016/j.cgh.2019.01.014.

M. Wagner, D.Samaha, R.Casciano, M. Brougham, P. Abrishami, C. Petrie, B. Avouac, L. Mantovani, A. Sarría-Santamera, P. Kind, M. Schlander:
Moving towards accountability for reasonableness: A systematic exploration of the features of legitimate healthcare coverage decision-making processes using rare diseases and regenerative therapies as a case study.
International Journal of Health Policy and Management, (2019) 8(7) 424-443.
DOI: 10.15171/ijhpm.2019.24.

R. Schaefer, M. Schlander:
Is the National Institute for Health and Care Excellence (NICE) in England more ´innovation-friendly´ than the Federal Joint Committee (GBA) in Germany?
Expert Review of Pharmacoeconomics & Outcomes Research, (2019) 19(4) 453-462.
DOI: 10.1080/14737167.2019.1559732.

J. J. Caro, J.E. Brazier, J. Karnon, P. Kolominsky-Rabas, A. J. McGuire, E. Nord, M. Schlander:
Determining value in Health Technology Assessment: Stay the course or tack away?
PharmacoEconomics, (2019) 37(3) 293-299.
DOI: 10.1007/s40273-018-0742-2.

J. Richardson, M. Schlander:
Health Technology Assessment (HTA) and economic evaluation: Efficiency or fairness first.
Journal of Market Access & Health Policy, (2019) 7(1) 1-12.
DOI: 10.1080/20016689.2018.1557981.

V. Jantzer, M. Schlander, J. Haffner, P. Parzer, S. Trick, F. Resch, M. Kaess:
The cost incurred by victims of bullying from a societal perspective: Estimates based on a German online survey of adolescents.
European Child and Adolescent Psychiatry, (2019) 28(4) 585-594.
DOI: 10.1007/s00787-018-1224-y.


M.-J. Linton, P. M. Mitchell, H. Al-Janabi, M. Schlander, J. Richardson, A. Iezzi, J. Ubels, J. Coast:
Comparing the German translation of the ICECAP-A capability wellbeing measure to the original English version: psychometric properties across healthy samples and seven health condition groups.
Applied Research in Quality of Life, First published: 7 DEC 2018
DOI: 1-23. 10.1007/s11482-018-9681-5.

M. Schlander, C.-Y. Cheng, T. Ran:
The health economics of cancer screening in Germany: Which population-based interventions are cost-effective? [Gesundheitsökonomie der Krebsfrüherkennung in Deutschland: Welche Interventionen sind kosteneffektiv bei bevölkerungsweiter Umsetzung?]
Bundesgesundheitsblatt, (2018) 61(12) 1559-1568.
DOI: 10.1007/s00103-018-2839-3.

J. Espin, M. Schlander, B. Godman, P. Anderson, J. Mestre-Ferrandiz, I. Borget, A. Hutchings, S. Flostrand, A. Paranby, C. Jommi:
Projecting pharmaceutical expenditure in EU5 to 2021: Adjusting for the impact of discounts and rebates.
Applied Health Economics and Health Policy, (2018) 16(6) 803-817.
DOI: 10.1007/s40258-018-0419-1.

K. Hernandez-Villafuerte, A. Fischer, N. R. Latimer:
Challenges and methodologies in using progression free survival as a surrogate for overall survival in oncology.
International Journal of Technology Assessment in Health Care, (2018) 34(3) 300-316.
DOI: 10.1017/S0266462318000338.


M. Schlander, C.-M. Dintsios, A. Gandjour:
Budgetary impact and cost drivers of drugs for rare and ultrarare diseases.
Value in Health, (2017) 21(5) 525-531.
DOI: 10.1016/j.jval.2017.10.015.

G. Steigner, C. Doarn, M. Schütte, D. Matusiewicz, C. Thielscher:
Health applications for corporate health management.
Telemedicine and E-Health, (2017) 23(5) 448-452.
DOI: 10.1089/tmj.2016.0162.

L. Annemans, S. Aymé, Y. Le Cam, K. Facey, P. Gunther, E. Nicod, M. Reni, J.-L. Roux, M. Schlander, D. Taylor, C. Tomino, J, Torrent-Farnell, S. Upadhyaya, A. Hutchings, L. Le Dez:
Recommendations from the European working group for value assessment and funding processes in rare diseases.
Orphanet Journal of Rare Diseases, (2017) 12 (50) 1-15.
DOI: 10.1186/s13023-017-0601-9.

K. Hernandez-Villafuerte, J. Sussex, E. Robin, S. Guthrie, S. Wooding:
Economies of scale and scope in publicly funded biomedical and health research: Evidence from the literature.
Health Research Policy and Systems, (2017) 15(3).
DOI: 10.1186/s12961-016-0167-3.

Non-refereed publications


M. Schlander:
Allen Patienten gerecht warden. Gedanken eines Gesundheitökonomen zur COVID-19-Krise.
Frankfurter Allgemeine Zeitung FAZ. May 29, 2020; No.124:p.20.


M. Schlander:
Opportunities for cooperation between the Division of Health Economics at DKFZ & Clinical Researchers (at U of Heidelberg, NCT, DKTK).
Heidelberg, April 17, 2019.

C. Thielscher,B. Krol, S. Heinemann, M. Schlander:
Ethical decomposition as a new method to analyse moral dilemmata.
INFORMATIK 2019, Hrsg: David, Geihs, Lange, Stumme.
Lecture Notes in Informatics (LNI), Gesellschaft für Informatik, Bonn 2019. DOI: 10.18420/inf2019_07



K. Hernandez-Villafuerte, B. Zamora, Y. Feng, D. Parkin, N. Devlin, A. Towse:
Exploring variations in the opportunity cost cost-effectiveness threshold by clinical area: Results from a feasibility study in England.
Office of Health Economics, (2018) OHE Research Paper 19/3.

M. Schlander, K. Hernandez-Villafuerte, C. Thielscher:
Cost of cancer in Germany [Kosten der Onkologie in Deutschland].
Forum, (2018) 33(5) 330-337.

K. Hernandez-Villafuerte, B. Zamora, A. Towse:
Issues surrounding the estimation of the opportunity cost of adopting a new health care technology: Areas for Further Research.
Office of Health Economics, (2018) OHE Research Paper 18/7.

A. Towse, K. Hernandez-Villafuerte, B. Shaw:
A critique of the paper “The estimated costs of production and potential prices for the World Health Organization Essential Medicines List”.
Office of Health Economics, (2018) OHE Consulting Report.

M. Schlander:
Was ist uns die Krebsversorgung wert?
360° Onkologie Krebs und Politik, (2018) 2(5) 4.

M. Schlander:
Das Schreckgespenst der Kostenexplosion ist nicht gut begründet.
Frankfurter Allgemeine Zeitung, April 13, 2018, V2.

H. Telser, B. Fischer, M. Schlander:
Knappe Ressourcen und unbegrenzte Wünsche.
Im Dialog - CSS Journal 1, (2018) 4-6.

M.Schlander, B. Fischer, H.Telser:
Mithilfe der Wissenschaft die Kosten bremsen.
Im Dialog - CSS Journal 1, (2018) 8-9.


T. Penzel, I. Flindell, R. Höger, U. Krämer, M. Schlander, J. Vogt, H.-E. Wichmann:
Evaluierung der Forschung zur Wirkung von Fluglärm auf den Menschen.
Interdisziplinäres Schlafzentrum Charité, Universitätsmedizin Berlin (2017).

C. Thielscher:
Was kann die Gesundheitswirtschaft von der Medizin lernen?
D. Matusiewicz, M. Muhrer-Schwaiger (eds.):
Neuvermessung der Gesundheitswirtschaft (2017) Springer, 253-268.

M. Schlander, O. Schwarz, G.-E. Trott:
Unanswered questions: ADHD in Germany: trends in diagnosis and pharmacotherapy [ADHS in Deutschland: Trends in Diagnose und medikamentöser Therapie].
Deutsches Ärzteblatt International (2017) 114(25): 428-429. DOI: 10.3238/arztebl.2017.0428a

M. Schlander:
Woran bemisst sich Effizienz im Gesundheitswesen? Zur Klärung fachwissenschaftlicher Begriffe und Kriterien.
Amos International, (2017) 11(1) 22-31.

M. Schlander:
Gescheiterte Börsenfusion – oder "Whatever it takes".
Frankfurter Allgemeine Zeitung, April 11, 2017: 6.

to top
powered by webEdition CMS